APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Agonists for the Treatment of both Diabetes and Obesity

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025172 pages

Choose your research edition.

Industry ResearchGLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity include Novo Nordisk and Eli Lilly among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Agonists for the Treatment of both Diabetes and Obesity revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Company

Novo Nordisk

Eli Lilly

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type

Tirzepatide

Semaglutide

Liraglutide

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of GLP-1 Agonists for the Treatment of both Diabetes and Obesity in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity industry.

Chapter 3: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Agonists for the Treatment of both Diabetes and Obesityrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Tirzepatide Table 3. Key Players of Semaglutide Table 4. Key Players of Liraglutide Table 4. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Retail Pharmacies Table 6. Key Players of Hospital and Clinic Table 7. Key Players of Other Table 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026) & (US$ Million) Table 10. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2021-2026) Table 11. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027-2032) & (US$ Million) Table 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region (2027-2032) Table 13. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends Table 14. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers Table 15. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges Table 16. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints Table 17. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Company (US$ Million) & (2021-2026) Table 18. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Company (2021-2026) Table 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Company Head Office and Area Served Table 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company, Product Type & Application Table 22. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 27. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 28. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021-2026) Table 29. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2027-2032) Table 30. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 32. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 33. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021-2026) Table 34. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2027-2032) Table 35. Novo Nordisk Company Information Table 36. Novo Nordisk Business Overview Table 37. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 39. Novo Nordisk Recent Development Table 40. Eli Lilly Company Information Table 41. Eli Lilly Business Overview Table 42. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio Table 44. Eli Lilly Recent Development Table 45. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 46. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 47. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 48. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 49. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 50. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) Table 51. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032) Table 52. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 53. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 54. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 55. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 56. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) Table 58. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032) Table 59. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 60. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 61. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 62. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 63. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 64. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 65. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 66. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 67. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) Table 69. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032) Table 70. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026) & (US$ Million) Table 71. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032) & (US$ Million) Table 72. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026) & (US$ Million) Table 73. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032) & (US$ Million) Table 74. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026) Table 76. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032) Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Image Figure 2. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type: 2025 VS 2032 Figure 4. Tirzepatide Image Figure 5. Semaglutide Image Figure 6. Liraglutide Image Figure 7. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application: 2025 VS 2032 Figure 9. Retail Pharmacies Image Figure 10. Hospital and Clinic Image Figure 11. Other Image Figure 12. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 14. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Players in 2025 Figure 17. Global Top 5 and 10 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Type (2021-2032) Figure 21. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue Market Share by Application (2021-2032) Figure 23. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 24. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032) Figure 25. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032) Figure 26. North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032) Figure 27. United States GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 28. Canada GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 29. Mexico GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 30. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 31. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032) Figure 32. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032) Figure 33. Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032) Figure 34. Germany GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 35. France GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 36. U.K. GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 37. Italy GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 38. Russia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 40. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 41. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032) Figure 42. China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032) Figure 43. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 44. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032) Figure 45. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032) Figure 46. Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032) Figure 47. Japan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 48. South Korea GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 51. India GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 52. Australia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032) Figure 57. Brazil GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 58. South Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 60. Turkey GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 61. Argentina GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 62. UAE GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 63. Egypt GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 64. Chile GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Tirzepatide
  • Semaglutide
  • Liraglutide
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • Novo Nordisk
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Tirzepatide
  5. 1.2.3 Semaglutide
  6. 1.2.4 Liraglutide
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Retail Pharmacies
  10. 1.3.3 Hospital and Clinic
  11. 1.3.4 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Growth Trends by Region
  14. 1.5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
  16. 1.5.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Dynamics
  1. 2.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
  2. 2.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers
  3. 2.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges
  4. 2.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue by Company (2021-2026)
  2. 3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Company Head office and Area Served
  4. 3.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company, Product Type & Application
  5. 3.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Revenue in 2025
  9. 3.6.3 2025 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Tier 1, Tier 2, and Tier 3
4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Type
  1. 4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2032)
  3. 4.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Share by Type (2021-2032)
5 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
  1. 5.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2032)
  3. 5.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Novo Nordisk
  2. 6.1.1 Novo Nordisk Company Information
  3. 6.1.2 Novo Nordisk Business Overview
  4. 6.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  6. 6.1.5 Novo Nordisk Recent Developments
  7. 6.2 Eli Lilly
  8. 6.2.1 Eli Lilly Company Information
  9. 6.2.2 Eli Lilly Business Overview
  10. 6.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
  12. 6.2.5 Eli Lilly Recent Developments
7 North America
  1. 7.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  2. 7.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  3. 7.2.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
  4. 7.2.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032)
  5. 7.2.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032)
  6. 7.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  7. 7.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
  8. 7.3.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032)
  9. 7.3.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032)
  10. 7.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
  11. 7.4.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
  13. 7.4.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
  14. 7.4.4 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  2. 8.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  3. 8.2.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
  4. 8.2.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032)
  5. 8.2.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032)
  6. 8.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  7. 8.3.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
  8. 8.3.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032)
  9. 8.3.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032)
  10. 8.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
  11. 8.4.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
  13. 8.4.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
  14. 8.4.4 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  2. 9.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  3. 9.2.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
  4. 9.2.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032)
  5. 9.2.3 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032)
  6. 9.3 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  7. 9.3.1 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
  8. 9.3.2 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032)
  9. 9.3.3 China GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  2. 10.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  3. 10.2.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
  4. 10.2.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032)
  5. 10.2.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032)
  6. 10.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  7. 10.3.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
  8. 10.3.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032)
  9. 10.3.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032)
  10. 10.4 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
  11. 10.4.1 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
  13. 10.4.3 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
  14. 10.4.4 Asia GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
  3. 11.2.1 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
  7. 11.3.1 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country
  11. 11.4.1 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst